Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Down 57.1% in May

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the target of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 57,741 shares, a decline of 57.1% from the May 14th total of 134,469 shares. Based on an average daily trading volume, of 40,907 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.5% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Price Performance

Shares of NASDAQ HKPD opened at $0.45 on Friday. Hong Kong Pharma Digital Technology has a 12 month low of $0.32 and a 12 month high of $2.58. The business’s 50 day moving average is $0.58 and its two-hundred day moving average is $0.69. The company has a quick ratio of 2.73, a current ratio of 2.93 and a debt-to-equity ratio of 0.28.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last posted its quarterly earnings data on Wednesday, March 18th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $3.57 million during the quarter.

Institutional Trading of Hong Kong Pharma Digital Technology

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. bought a new position in shares of Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned approximately 0.39% of Hong Kong Pharma Digital Technology as of its most recent SEC filing.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.